NASDAQ:IMMU Immunomedics (IMMU) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$87.86▼$87.8650-Day Range$85.08▼$87.8652-Week Range$8.80▼$87.93VolumeN/AAverage Volume4.01 million shsMarket Capitalization$20.31 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Immunomedics alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Immunomedics Stock (NASDAQ:IMMU)Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. IMMU Stock News HeadlinesMay 9, 2024 | finance.yahoo.comDecoding Gilead Sciences Inc (GILD): A Strategic SWOT InsightMay 6, 2024 | benzinga.comGilead Sciences Unusual Options Activity For May 06July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 3, 2024 | bizjournals.comGilead cuts jobs, trims drugs amid deeper biopharma pullbackApril 25, 2024 | msn.comGilead Sciences (GILD) Q1 2024 Earnings Call TranscriptApril 25, 2024 | marketwatch.comGilead Sciences Posts Higher 1Q Sales, Swings to Loss on ChargesApril 25, 2024 | msn.comGilead posts quarterly loss on acquisition charge, revenue rises 5%April 19, 2024 | markets.businessinsider.comThe Analyst Verdict: Gilead Sciences In The Eyes Of 12 ExpertsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.April 18, 2024 | benzinga.comWhat the Options Market Tells Us About Gilead SciencesApril 15, 2024 | finance.yahoo.comNorthStar Appoints Peter Pfreundschuh to Board of ManagersMarch 6, 2024 | finance.yahoo.comGilead bets on ‘trispecifics’ in latest cancer drug dealFebruary 29, 2024 | finance.yahoo.comAbingworth invests in Trodelvy development in deal with GileadFebruary 13, 2024 | msn.comGilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to PipelineFebruary 12, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead: Maintaining Our $97 Fair Value Estimate as CymaBay Acquisition Looks Like a Good FitFebruary 12, 2024 | finance.yahoo.comGilead to buy CymaBay in $4.3B deal for liver disease drugFebruary 7, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead Earnings: Maintaining $97 Fair Value Estimate as HIV and Oncology Catalysts ApproachJanuary 22, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead: Trodelvy Lung Cancer Data Disappoints, but No Changes to Our Fair Value EstimateSee More Headlines Receive IMMU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2020Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryBiotechnology Current SymbolNASDAQ:IMMU CUSIP45290710 CIK722830 Webwww.immunomedics.com Phone973-605-8200FaxN/AEmployees366Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-357,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-132.40% Return on Assets-51.32% Debt Debt-to-Equity RatioN/A Current Ratio12.84 Quick Ratio12.58 Sales & Book Value Annual Sales$290,000.00 Price / Sales70,028.66 Cash FlowN/A Price / Cash FlowN/A Book Value$1.38 per share Price / Book63.67Miscellaneous Outstanding Shares231,144,000Free FloatN/AMarket Cap$20.31 billion OptionableOptionable Beta2.90 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Behzad Aghazadeh Ph.D. (Age 49)Exec. Chairman Comp: $147.53kMr. Usama Malik (Age 45)CFO & Chief Bus. Officer Comp: $533.39kMr. Brendan P. Delaney (Age 45)Chief Commercial Officer Comp: $527.63kMr. Bryan Ball (Age 50)Chief Quality Officer Comp: $646.48kMr. William Fricker (Age 55)Principal Accounting Officer, Exec. Director & Corp. Controller Ms. Phyllis ParkerDirector of Admin.Dr. Chau ChengSr. Director of Investor RelationsMr. Jared Freedberg (Age 52)Gen. Counsel & Corp. Sec. Mr. Kurt J. W. Andrews (Age 51)Chief HR Officer Dr. Loretta M. Itri (Age 70)Chief Medical Officer More ExecutivesKey CompetitorsLantheusNASDAQ:LNTHBiogenNASDAQ:BIIBAlnylam PharmaceuticalsNASDAQ:ALNYBioMarin PharmaceuticalNASDAQ:BMRNUnited TherapeuticsNASDAQ:UTHRView All Competitors IMMU Stock Analysis - Frequently Asked Questions How were Immunomedics' earnings last quarter? Immunomedics, Inc. (NASDAQ:IMMU) issued its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.39. The biopharmaceutical company earned $20.07 million during the quarter, compared to analysts' expectations of $24.81 million. What other stocks do shareholders of Immunomedics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunomedics investors own include Micron Technology (MU), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Novavax (NVAX) and Gilead Sciences (GILD). This page (NASDAQ:IMMU) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunomedics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunomedics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.